Printer Friendly

BTG plc treats first liver tumour patient with DC Bead LUMI at the Wesley Hospital, Brisbane, Diagnostic and Interventional Radiologist.

M2 EQUITYBITES-January 22, 2019-BTG plc treats first liver tumour patient with DC Bead LUMI at the Wesley Hospital, Brisbane, Diagnostic and Interventional Radiologist

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Healthcare company BTG plc (LSE:BTG) said on Monday that an Australian patient has been dosed with its DC Bead LUMI for the local treatment of hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer (mCRC), respectively.

Dr Duncan Walker and his team reportedly performed transarterial chemoembolisation (TACE) using DC Bead LUMI on the Australian patient with liver tumours at the Wesley Hospital, Brisbane, Diagnostic and Interventional Radiologist.

The company added that the DC Bead LUMI, which is a next-generation DC Bead, is the first commercially available Radiopaque Drug-Eluting Bead that can be loaded with doxorubicin or irinotecan for the local treatment of hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer (mCRC), respectively.

According to the company, the DC Bead LUMI offers a personalised approach to treatment and a new level of control to TACE procedures. The lasting radiopacity allows the physician to see rather than assume where the beads are placed in the tumour, providing reassurance to patients that the treatment is getting to where it needs to be.

In addition, the DC Bead is the only drug-eluting bead with CE Mark approval for loading with doxorubicin or irinotecan, providing an effective standardised liver-directed therapy for primary and metastatic liver cancer. The ten years of clinical experience and extensive peer-review evidence supports its benefits, concluded the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 22, 2019
Words:261
Previous Article:Slayback Pharma unveils Hydroxyprogesterone Caproate Injection, USP 1,250mg/5ml in multi-dose vial.
Next Article:ViaCyte & Center for Beta Cell Therapy in Diabetes partnership begins clinical trial of human stem cell-derived implants in Type 1 diabetes patients...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters